Last reviewed · How we verify

NCT03757611

Efficacy and Safety of Tabetri on Osteoarthritis

Completed NA Last updated 30 November 2018
What this trial tests

NA trial testing Tabetri capsule in Osteoarthritis in 100 participants. Completed in 15 June 2018.

Timeline
31 July 2017
Primary endpoint
13 March 2018
15 June 2018

Quick facts

Lead sponsorJaseng Medical Foundation
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposesupportive care
Enrollment100
Start date31 July 2017
Primary completion13 March 2018
Estimated completion15 June 2018
Sites4 locations across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Jaseng Medical Foundation

Who can join

Adults 40 to 75, any sex, with Osteoarthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a 12-week, multicenter, randomized, double-blind, placebo-controlled clinical trial in order to evaluate the efficacy and safety of tabetri on osteoarthritis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Osteoarthritis

Currently open trials in the same condition.

Other Jaseng Medical Foundation trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03757611.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing